Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Share-based Compensation: 2010-2025

Historic Share-based Compensation for Anika Therapeutics (ANIK) over the last 14 years, with Sep 2025 value amounting to $2.1 million.

  • Anika Therapeutics' Share-based Compensation fell 38.63% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year decrease of 32.74%. This contributed to the annual value of $13.1 million for FY2024, which is 13.86% down from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' Share-based Compensation is $2.1 million, which was down 18.25% from $2.5 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Share-based Compensation ranged from a high of $4.2 million in Q2 2023 and a low of $2.1 million during Q3 2025.
  • In the last 3 years, Anika Therapeutics' Share-based Compensation had a median value of $3.6 million in 2023 and averaged $3.3 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first spiked by 1,191.30% in 2021, then tumbled by 40.89% in 2024.
  • Anika Therapeutics' Share-based Compensation (Quarterly) stood at $3.2 million in 2021, then grew by 20.44% to $3.8 million in 2022, then climbed by 0.05% to $3.8 million in 2023, then crashed by 40.89% to $2.3 million in 2024, then tumbled by 38.63% to $2.1 million in 2025.
  • Its last three reported values are $2.1 million in Q3 2025, $2.5 million for Q2 2025, and $3.0 million during Q1 2025.